Intestinal microbiota in functional bowel disorders: a Rome foundation report
Top Cited Papers
Open Access
- 22 June 2012
- Vol. 62 (1), 159-176
- https://doi.org/10.1136/gutjnl-2012-302167
Abstract
It is increasingly perceived that gut host–microbial interactions are important elements in the pathogenesis of functional gastrointestinal disorders (FGID). The most convincing evidence to date is the finding that functional dyspepsia and irritable bowel syndrome (IBS) may develop in predisposed individuals following a bout of infectious gastroenteritis. There has been a great deal of interest in the potential clinical and therapeutic implications of small intestinal bacterial overgrowth in IBS. However, this theory has generated much debate because the evidence is largely based on breath tests which have not been validated. The introduction of culture-independent molecular techniques provides a major advancement in our understanding of the microbial community in FGID. Results from 16S rRNA-based microbiota profiling approaches demonstrate both quantitative and qualitative changes of mucosal and faecal gut microbiota, particularly in IBS. Investigators are also starting to measure host–microbial interactions in IBS. The current working hypothesis is that abnormal microbiota activate mucosal innate immune responses which increase epithelial permeability, activate nociceptive sensory pathways and dysregulate the enteric nervous system. While we await important insights in this field, the microbiota is already a therapeutic target. Existing controlled trials of dietary manipulation, prebiotics, probiotics, synbiotics and non-absorbable antibiotics are promising, although most are limited by suboptimal design and small sample size. In this article, the authors provide a critical review of current hypotheses regarding the pathogenetic involvement of microbiota in FGID and evaluate the results of microbiota-directed interventions. The authors also provide clinical guidance on modulation of gut microbiota in IBS.Keywords
This publication has 163 references indexed in Scilit:
- A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndromeInternational Journal of Colorectal Disease, 2011
- Gastrointestinal Microbiome Signatures of Pediatric Patients With Irritable Bowel SyndromeGastroenterology, 2011
- Therapies Aimed at the Gut Microbiota and Inflammation: Antibiotics, Prebiotics, Probiotics, Synbiotics, Anti-inflammatory TherapiesGastroenterology Clinics of North America, 2011
- Rifaximin Therapy for Patients with Irritable Bowel Syndrome without ConstipationNew England Journal of Medicine, 2011
- Dominant and diet-responsive groups of bacteria within the human colonic microbiotaThe ISME Journal, 2010
- The gut microbiota shapes intestinal immune responses during health and diseaseNature Reviews Immunology, 2009
- A core gut microbiome in obese and lean twinsNature, 2008
- A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndromeGastroentérologie Clinique et Biologique, 2008
- Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseasesProceedings of the National Academy of Sciences, 2007
- The gut flora as a forgotten organEMBO Reports, 2006